Source:http://linkedlifedata.com/resource/pubmed/id/16189725
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2005-9-28
|
| pubmed:abstractText |
Adult medulloblastoma is a rare tumor with few retrospective studies published so far. The role of adjuvant chemotherapy or chemotherapy at relapse is unclear. This study reports therapy and outcome in all adult (>or=16 years old) medulloblastoma (n=34) and supratentorial primitive neuroectodermal tumor (PNET) patients (n=2) treated in 2 neuro-oncological centers between 1976 and 2002. The median age was 24.5 years (range 16-76). After resection, 16 patients were treated with craniospinal radiotherapy alone, 20 patients also received adjuvant chemotherapy (8 vincristine, CCNU, cisplatin; 7 methotrexate alone or methotrexate/vincristine-based polychemotherapy; 5 other protocols). Median survival in the whole cohort was 126 months (2+ - 200+months). Five-year and 10-year survival rates were 79 % and 56%. Adjuvant chemotherapy was associated with a non-significant trend to prolonged survival (relative risk (RR) 1.89; p=0.068). The median progression-free survival (PFS) after primary therapy was 83 months. At relapse, 10 of 12 evaluable patients achieved a complete response upon second-line therapy. The median survival times from first (n=17) and second relapse (n=9) were 21 months (0-67+ months; 5/17 without second relapse) and 20 months (1-29 months). Cox regression analysis revealed the infiltration of the floor of the 4(th) ventricle at diagnosis as the only therapy-independent prognostic factor (RR 0.48; p=0.03). In conclusion, adjuvant chemotherapy may prolong survival in adult medulloblastoma patients. Moreover, second-line therapy may be beneficial for these patients. As in pediatric medulloblastoma patients, primary infiltration of the floor of the 4(th) ventricle indicates a poor prognosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0340-5354
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
252
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
291-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16189725-Adolescent,
pubmed-meshheading:16189725-Adult,
pubmed-meshheading:16189725-Aged,
pubmed-meshheading:16189725-Analysis of Variance,
pubmed-meshheading:16189725-Cerebellar Neoplasms,
pubmed-meshheading:16189725-Combined Modality Therapy,
pubmed-meshheading:16189725-Demography,
pubmed-meshheading:16189725-Disease Progression,
pubmed-meshheading:16189725-Disease-Free Survival,
pubmed-meshheading:16189725-Dose-Response Relationship, Radiation,
pubmed-meshheading:16189725-Drug Therapy,
pubmed-meshheading:16189725-Female,
pubmed-meshheading:16189725-Humans,
pubmed-meshheading:16189725-Male,
pubmed-meshheading:16189725-Medulloblastoma,
pubmed-meshheading:16189725-Middle Aged,
pubmed-meshheading:16189725-Radiotherapy, High-Energy,
pubmed-meshheading:16189725-Recurrence,
pubmed-meshheading:16189725-Regression Analysis,
pubmed-meshheading:16189725-Retrospective Studies,
pubmed-meshheading:16189725-Risk Factors,
pubmed-meshheading:16189725-Time Factors,
pubmed-meshheading:16189725-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse.
|
| pubmed:affiliation |
Department of Neurology, Hertie Institute for Clinical Brain Research University of Tübingen Medical School, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany. ulrich.herrlinger@uni-tuebingen.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|